PharVision Advisers’s Xerox XRX Stock Holding History

PharVision Advisers’s Portfolio XRX Stock Details XRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-87,018	Closed	-$206K	–	661
2025 Q4	$206K	Buy	87,018 +40,194	+86%	+$119K	0.1%	534
2025 Q3	$176K	Buy	+46,824	New	+$207K	0.1%	543

Other funds holding XRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PharVision Advisers's XRX Position: Q1 2026 in Review

PharVision Advisers sold out of Xerox (XRX) in Q1 2026, closing a stake of 87,018 shares — an estimated $206K sold.

PharVision Advisers first reported a position in XRX in Q3 2025 and held it in 2 quarters. The position peaked at $206K in Q4 2025. 220 funds tracked by Wall St. Rank hold XRX as of Q1 2026.

PharVision Advisers reported no remaining Xerox position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 87,018 Xerox shares in Q1 2026, an estimated $206K.
PharVision Advisers first reported a position in Xerox in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Xerox position peaked at $206K in Q4 2025.
220 funds tracked by Wall St. Rank held Xerox as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.